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Interleukin-l (IL-I) is a proinflammatory cytokine which was
originally described as a product of activated mononuclear
phagocytes, but is now known to be released by many cell
types. Systemically, IL-I induces fever, the acute phase re-
sponse, and neutrophilia. Locally it mediates tissue injury and
remodelling by inducing cells to undergo a coordinated re-
sponse that culminates in the expression of new structural
determinants and functional characteristics. IL-I is encoded by
at least two distinct genes which may have arisen by a reverse
transcriptase-mediated duplication. Two IL-i receptors have
been identified. The 80 kD receptor present on T cells and
connective tissue cells has been cloned. The cytoplasmic do-
main of this receptor does not contain sequences with homol-
ogy to the known catalytic domains of tyrosine or serine/
threonine-specific protein kinases. A second 67 kD IL-I
receptor has also been demonstrated by cross linking on mono-
cyte-macrophages, but its sequence has not been published.
The molecular biology, biochemistry and structure of IL-i and
its receptors has been extensively reviewed and will not be
further discussed [1, 2].
Interleukin-1, mesangial cells and glomerular injury
Of all the cytokines, the synthesis of IL-i by glomerular cells
and the actions of IL-i on glomerular cells has been best studied
in a number of labs [3 and references therein]. Lovett and his
colleagues originally demonstrated that proliferating, cultured
rat mesangial cells produced an IL-i-like cytokine, originally
termed mesangial cell-derived thymocyte activating factor,
which was an endogenous pyrogen. Both they and we demon-
strated concurrently that cultured human and rat mesangial
cells, respectively, contain transcripts which migrate on North-
ern analyses with macrophage IL-la and IL-l/3. The p1 and
molecular weights of rat and human mesangial cell IL-i proteins
are indistinguishable from macrophage IL-la and IL-i13. The
transcriptional and post-transcriptional regulation of mesangial
cell IL-i biosynthesis was further addressed by Lovett et al.
Serum, platelet-derived growth factor and epidermal growth
factor in combination, the terminal attack complex of comple-
ment, and endotoxin (LPS) appear to increase mesangial cell
IL-I production. Mesangial cell-derived, as well as m000cyte-
derived, lI-la and IL-l/3 are myristylated after translation.
In addition to synthesizing IL-l, cultured human and rat
mesangial cells have IL-i receptors. Scatchard analysis of
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mesangial cell binding of radioiodinated IL-ia and IL-l/3 re-
vealed a single class of high affinity receptors with a Kd of 5.5
X lOt' M and approximately 4,000 receptors per cell. Using
RNA-RNA solution hybridization, we have demonstrated fur-
ther that mesangial cells express mRNA transcripts for the T
cell/fibroblast type IL-i receptor (J.R. Sedor, unpublished
observations).
IL-i induces a variety of biochemical and functional re-
sponses in mesangial cells. IL-i is a co-mitogen for cultured
mesangial cells. Purified rat IL-i enhanced the proliferative
rates of mesangial cells only in the presence of serum, To
address this issue further, we used a fully defined medium that
supports mesangial cell growth. Addition of fibroblast growth
factor (FGF) at submitogenic concentrations or IL-ia did not
further enhance the proliferation of growth-arrested cells in-
duced by changing from holding to defined medium. However,
IL-ia and FGF synergistically increased 3H-thymidine incor-
poration, suggesting that the signalling pathways activated by
interleukin-la alone will not induce cell growth. Stahl and his
coworkers have recently extended these observations and have
demonstrated that, although rat recombinant 11-1/3 is a mesan-
gial cell co-mitogen, endogenous prostaglandin E2 formation,
which is also stimulated by the addition of the cytokine,
antagonizes the growth promoting activities of the cytokine.
When prostaglandin synthesis was inhibited by indomethacin,
IL-1/3-induced cell proliferation was sevenfold greater com-
pared with IL-i alone, In addition to being a comitogen, both
macrophage and mesangial cell-derived IL-I stimulate cultured
mesangial cells to generate prostaglandin E2, to synthesize
collagen, to produce and secrete the neutrophil chemotactic
peptide interieukin-8 and to enhance secretion of a glomerular
basement membrane-degrading, neutral protease. A recent re-
port has also demonstrated that these cells in culture produce
significant amounts of superoxide anion and hydrogen peroxide
after exposure to IL-1/3.
A number of studies have now implicated intrarenal IL-I
synthesis and release in the pathogenesis of experimental and
human glomerular injury. By dot blot hybridization, we have
demonstrated a two- to three-fold increase of IL-i transcripts in
total RNA extracted from kidneys of rats with immune complex
glomerulonephritis compared to that extracted from healthy
rats. Kelley and co-workers in a series of studies have demon-
strated that IL-l/3, but not IL-la, mRNA and protein expres-
sion are increased in renal cortex in two strains of mice with
autoimmune disease which mimics systemic lupus nephritis.
Glomeruli from rats and rabbits with accelerated autologous
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anti-GBM disease, when maintained in short-term culture,
produce significantly more IL-I activity than controls. Glomer-
uli from rabbits with a heterologous anti-GBM disease produce
less IL-i activity. Exogenous recombinant IL-i increases the
severity of glomerular injury in a passive model of anti-GBM
nephritis in rats. Mesangiopathic glomerulonephritis with pre-
dominant IgA deposits, induced in mice by dextran immuniza-
tion, is associated with a time-dependent increase in the expres-
sion of IL-i/3 but not IL-la (J.R. Sedor, S.N. Emancipator, et
al, unpublished observations). Diamond et al have been able to
identify cells, probably glomerular macrophages, within the
glomerular mesangium that stained for IL-I during acute ami-
nonucleoside nephrosis. Studies in humans are limited, but
Atkins has found enhanced IL-i bioactivity in glomerular
culture supernatants in three patients with rapidly progressive
crescentic glomerulonephritis.
Interleukin-1 and mesangial cell activation
As a result of the studies summarized above, many investi-
gators have hypothesized that IL-i-activated mesangial cells,
within the inflamed glomerulus, express an activated phenotype
that contributes to the progression of glomerular injury. How-
ever, the molecular and biochemical events which modulate
this cytokine-induced transition of mesangial cell differentiation
are poorly understood.
The early transmembrane signalling pathways activated by
IL-i in mesangial cells have been studied in some detail. We
initially focused on the phospholipid-derived and ionic signals
that may have mediated the effects of IL-i on cultured mesan-
gial cells [4]. IL-I a induced a rapid increase in 1 ,2-diacylglyc-
erol formation which peaked at one minute. IL-ia had no effect
on inositol phosphate or cystolic calcium concentrations,
demonstrating that IL-i does not activate an inositol phospho-
lipid-specific phospholipase C. We also found that 3H-phos-
phorylethanolamine, but not 3H-phosphorylserine or 3H-phos-
phorylcholine, was maximally elevated at one minute in
mesangial cells incubated with IL-i. Radioactivity incorporated
into phosphatidylethanolamine, but not phosphatidylcholine,
was also decreased in IL- 1-stimulated mesangial cells compared
with control at one minute. These data suggest that IL-i
activates a phospholipase C in mesangial cells which is predom-
inantly linked to phosphatidylethanolamine. In contrast to other
mitogens, IL-i did not alter intracellular pH in mesangial cells
[4]. Bursten and coworkers have also shown, in cultured
mesangial cells, rapid IL- 1-stimulated diacylgiycerol formation
from phosphatidic acid by phosphatidic phosphohydrolase [5],
a mechanism similar to that described by the same investigators
for Lipid A [6].
The effects of IL-i on other early transmembrane signalling
pathways have also been studied. Pfeilschifter and his col-
leagues have recently demonstrated that IL-if3 did not stimulate
cyclic AMP formation in incubations as long as 24 hours [7] but
did increase cyclic GMP formation after four to eight hours [8].
Regulation of cell function often involves changes in protein
phosphorylation. In vitro, IL-i stimulated the rapid phosphor-
ylation of several plasma proteins, which are 52 to 55 kD, 46 kD
and 20 kD in size [91. The 46 kD phosphoprotein, which was
most prominently phosphorylated, contained phosphotyrosine
when examined by phosphoamino acid analysis. The 52 to 55
kD and 20 kD phosphoproteins were alkaline-labile and con-
tamed phosphoserine. In addition, we have recently found that
IL-i does not change the phosphorylation state of the putative
80 kD substrate of protein kinase C (J.R. Sedor, unpublished
data). Taken together, these studies suggest that IL-i induces
an activated mesangial cell phenotype by stimulating early
transmembrane signalling mechanisms that are independent of
both protein kinase C and cyclic AMP-dependent protein kinase
activation.
Studies in other cell types have demonstrated that IL-i
stimulates rapid I ,2-diacylglycerol formation, induces cAMP
accumulation and activation of the cAMP-dependent protein
kinase, increases protein kinase C activity, activates a pertussis
toxin-sensitive G protein and enhances Na/H antiporter
activity in some but not all target cells [1, 10]. The lack of a
unifying description of the biochemical events activated when
IL- 1 interacts with its receptor suggests either different signal-
ling pathways are activated by this cytokine in different cells, or
that a common signal transducing pathway has yet to be
defined. A recent study has indicated that, in human foreskin
fibroblasts, IL-i activates a kinase cascade that involves mito-
gen-activated peptide (MAP) kinase as well as a novel threo-
nine/serine kinase [11], but the universality of these findings or
the mechanisms(s) of activation of these kinases have as yet to
be determined.
The mechanisms involved in the translation of these early
events into a cellular response are essentially unstudied in
mesangial cells. In other cells, IL-i rapidly induces the expres-
sion of AP- 1 transacting factors, activates the transacting factor
NF-kB, and can enhance IL-6 gene expression through a 23-bp
multiple response element (MRE). The mechanisms by which
IL-i regulates these transacting activities has been most com-
pletely studied for NFkB. Bomsztyk et al have recently dem-
onstrated that IL-i activates NF-kB by pathways independent
of protein kinase C in both a B and T cell line [12]. This finding
is consistent with a number of studies suggesting that the
cytokine stimulates a kinase cascade that does not involve
PKC. These same investigators have also identified a 65 kD
kB-associated protein, which is phosphorylated by a nuclear
kinase [13]. In vitro, the 65 kD protein was phosphorylated in
the absence of added kinase and this kinase activity could not
be separated from the 65 kD NF-kB-associated protein. This
data suggests a novel mechanism of gene regulation by IL-i in
which a nuclear protein kinase is closely associated with a
sequence specific DNA. Whether this 65 kD phosphoprotein is
the same protein as the 65 kD NF-kB trans-modulator has yet to
be determined.
In summary, both the IL-i activated, short- and long-term
signalling pathways need to be clarified further. However, in
addition to cell-specific responses described above, evidence is
mounting that this cytokine activates a protein kinase(s) in a
number of cell types, including the mesangial cell. Further
identification of the specific protein kinases activated and of
both the ubiquitous and cell-specific mechanisms that regulate
these kinase cascades, is integral to understanding how IL-i
induces cellular responses.
Interleukin-1, phospholipase A2 and the mesangial cell
Enhanced PLA2 activity has been implicated in receptor-
mediated signalling events. Free arachidonate or its metabolites
may function as second messengers that induce gene expression
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[14, 15] activate transacting factors [16], and regulate K
channels [17, 18]. IL-i-mediated PLA2 induction may be a key
step that, in concert with other signals, culminates in the
synthesis of critical mediators of inflammation, including pros-
taglandins, leukotrienes, and platelet activating factor, and
initiates a specific program of responses by the target cell.
PLA2 enzymes of mammalian origin have traditionally been
classified into groups based upon similarities in primary struc-
ture to various snake venom PLA2s [19]. Mammalian Type I
PLA2 are 14 kD proteins which have homology with elapid
viper venom. They were first characterized in pancreatic ex-
tracts and have now been isolated from gastric mucosa, splenic
supernatants, lung and spleen. The non-pancreatic 14 kD Type
II enzyme was initially isolated from venoms of Crotalidae and
Viperidiae, and mammalian homologues have been isolated
from rat splenic membranes, peritoneal exudates, synovial
fluid, rat platelet and porcine intestine. Recently a large 110 kD
soluble form of PLA2 has been purified by Gronich, Bonventre
and Nemenoff from rat kidney [20]. Another group concurrently
purified this protein from the human monocyte cell line U937
[21]. Unlike the Type I and II forms, this enzyme is activated as
physiologic, micromolar calcium concentrations and specifi-
cally hydrolyzes arachidonyl-phospholipids. All three forms of
PLA2 have been cloned. While the small forms have significant
homology to each other, the large form has a unique structure
with no similarities to the Type I and Type II PLA2s. The
precise functions of each protein in basic physiological and
pathological processes, although currently unclear, can now be
addressed.
Since enhanced prostaglandin production characterizes gb-
merular inflammation, we have recently used the mesangial cell
as a model system to study IL-l-stimulated prostaglandin
synthesis and to define the effects of this cytokine on arachido-
nate availability and PLA2 activity and synthesis [22]. Serum
was required for extended mesangial cell prostaglandin forma-
tion. Both cycboheximide and actinomycin D inhibited IL-l-
induced prostaglandin production. In vitro, phospholipase ac-
tivity was increased five- to tenfold in acid extracts of IL-l-
treated cells, as measured by arachidonate release from
exogenous '4C-arachidonylphosphatidylethanolamine. This
phospholipase activity was calcium-dependent and inhibited by
phospholipase A2 inhibitors. A sensitive and specific solution
hybridization assay demonstrated coordinate, time-dependent
induction of nonpancreatic (Type II) phospholipase A2 mRNA
transcripts. The Type I form of PLA2 was not identified in rat
mesangial cells (Fig. 1), and while mesangial cells express the
soluble 110 kD PLA2 [19], it is not known whether cytokines
regulate the activation or synthesis of this form of the enzyme.
In whole cells, basal arachidonate release was equivalent in
vehicle- and IL-i-primed cells, but vasopressin-stimulated
arachidonate release was potentiated two- to threefold by IL-i
pretreatment, suggesting that IL-i may prime cells for in-
creased prostaglandin synthesis by increasing phospholipase A2
activity. Our data demonstrate that IL-i induces a nonpancre-
atic phospholipase A2 and imply that IL-I directly stimulates,
as well as primes cells for, enhanced prostaglandin synthesis, in
part, by increasing phospholipase A2 activity through enzyme
synthesis.
Pfeilschifter and his coworkers have also shown that IL-l/3
stimulated mesangial cell phospholipase A2 activity [7]. They
Phospholipase A2
Fig. 1. Type I phospholipase A2 is not detectable in serum or IL-i
stimulated mesangial cells. Equivalent amounts of protein (50 pg/lane)
from lysates of rat mesangial cells, maintained in 5% serum and
exposed to IL-i or vehicle control for 24 hours, were processed for
immunoblotting as described in reference 22. Purified porcine (Type I)
PLA2 was included as a positive control. Type I PLA2 was detected
using a rabbit anti-porcine pancreatic PLA2 antisera (provided by Drs.
L. Graziadei and D. Bar-Sagi, see [22]). This antisera has been
successfully used to detect Type I PLA2 in rat fibroblasts. Specificity of
the 14 kD immunoreactive band was demonstrated in a parallel immu-
nobbot by using the antiserum which had been preabsorbed for 15
minutes with excess authentic pancreatic PLA2 prior to use.
recently have characterized by immunobbotting the IL-i-stimu-
lated mesangial cell phospholipase A2 activity as a nonpancre-
atic (Type II) phospholipase A2 [23]. The role of different
second messenger systems in the regulation or reconstitution of
the induction of phospholipase A2 mRNA by IL-i has also been
studied by us and others [23—25, Table 1]. Similar to astrocytes
[24] and vascular smooth muscle cells [25], forskolin, a cAMP
agonist, potentiated Type II PLA2 induction by IL-i in mesan-
gial cells. However, forskolin alone only induced PLA2 mRNA
in VSM, but had no effect in mesangial cells or astrocytes.
Others have found that forskolin increases PLA2 secretion and
protein expression in rat mesangial cells [7, 23]. The protein
kinase agonist, phorbol 12-myristate- 13-acetate (PMA), only
stimulated expression of PLA2 in astrocytes. In mesangial cells,
serum deprivation for 24 hours enhances, and co-incubation of
IL-i with PDGF inhibits, IL-I-stimulated PLA2 expression.
These data suggest that IL-I specifically activates transcription
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Table 1. Cell-specific reg
mR
ulation of IL-i
NA expression
induced Type II PLA2
Cell cAMP cAMP/IL-I PMA PDGF
RMC — + — +
VSMb + + —
Astrocytec — + + ?
Abbreviations are: RMC, rat mesangial cell; VSM, vascular smooth
muscle cell.
J.R. Sedor, unpublished datab Data taken from reference 25
Data taken from reference 24
Summary and prospects
A number of avenues are open for future studies. The cellular
source of enhanced IL-I synthesis needs to be defined by
immunohistochemistry and in situ hybridization in both exper-
imental models and human glomerulonephritis. Even more
critical, studies of reagents that prevent IL-i from reaching its
target cells (for example, monoclonal antibodies, soluble IL-I
receptors, IL-i receptor antagonists), need to be performed to
ultimately determine the contribution of this cytokine to gb-
merular injury. Such studies could provide the basis for use of
these reagents as therapies for a disease which has few effective
treatments.
Equally intriguing are the basic cell biological questions
raised by earlier work. Much of what is known about the effects
of IL-i on the mesangial cell are general mechanism of signal-
ling and gene activation. The pathways controlling a ligand-
specific cellular response have yet to be defined for many
peptides. Understanding how IL-i-stimulated mesangial cell
genes are controlled may identify cell-specific genes or regula-
tory pathways that would identify unique IL-i signals and
define, on a molecular and biochemical level, the cytokine-
activated mesangial cell phenotype.
The data summarized above suggest that the mesangial cell is
a key participant in generating and responding to a network of
polypeptide cytokines, which are important in the pathogenesis
of glomerulonephritis. Future experimentation will undoubt-
edly further define the importance of polypeptide cytokines in
the pathogenesis of glomerulonephritis and characterize the
molecular mechanisms underlying the response of the mesan-
gial cell to inflammatory injury.
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